Immunization Service

Cell Immunization

Small molecule Immunization

Our company currently operates a large-scale alpaca breeding base in the Donghu High-tech Zone of Wuhan. With a capacity for immunizing up to 100 adult animals annually, it is well-equipped to meet the demand for a substantial volume of antigen immunizations.

Multi‑pass transmembrane proteins are key drug targets.NBLST provides proprietary VLP and Nanodisc platforms to prepare high‑quality immunogens and screening antigens in native conformation.

RNA immunity is an emerging strategy widely recognized during COVID-19.Inside the body, RNA translates into heterologous proteins, activating T cells and antibody responses.RNA is delivered by lipid nanoparticles (LNP) with inherent immunogenicity, requiring no extra adjuvants.Linear, circular and self-amplifying RNA are widely applied. NBLST offers one-stop solutions for RNA-LNP preparation, RNA immunity and nanobody development, ensuring quality and high efficiency.